Biologics: Targets and Therapy

Dove Medical Press is pleased to invite you to the upcoming Article Collection “Cancer Radiotherapeutic Targets for Enhanced Radiosensitization and/or Radioprotection Strategies” led by Professor Shuyu Zhang, Professor Shun Lu, and Professor Wenling Tu in Biologics: Targets and Therapy.

Cancer radiotherapy, a cornerstone in cancer treatment, continually evolves to enhance its efficacy and minimize side effects. This Article Collection delves into the pivotal theme of "Cancer Radiotherapeutic Targets for Enhanced Radiosensitization and/or Radioprotection Strategies." Radiosensitization involves making cancer cells more susceptible to radiation, while radioprotection focuses on safeguarding surrounding healthy tissues. Understanding and manipulating these targets can revolutionize radiotherapy outcomes. From molecular pathways to novel therapeutic agents, this Collection explores the diverse strategies employed to augment the precision and safety of cancer radiotherapy.

The significance of identifying targets for radiosensitization and radioprotection lies in the potential to optimize cancer treatment outcomes. By deciphering the molecular and cellular intricacies underlying these processes, researchers can fine-tune radiotherapeutic approaches, maximizing effectiveness while minimizing collateral damage. This Collection aspires to contribute to the evolution of personalized and targeted cancer treatments, heralding a new era in which patients experience improved responses and reduced side effects.

We invite contributions spanning various subjects within cancer radiotherapy. Subtopics include the identification of novel molecular targets, exploration of emerging therapeutic agents, and advancements in technology facilitating precision treatments. Original research articles, reviews, and clinical studies are sought to create a mosaic of insights that align with the journal's commitment to disseminating impactful research in the broader field of oncology. This Collection aims to catalyze discussions and foster collaborations to drive further innovation in the realm of cancer radiotherapy.

Keywords

Cancer Radiotherapy, Radiosensitization, Radioprotection, Molecular Targets, Therapeutic Advancements

All manuscripts submitted to this Article Collection will undergo desk assessment and a full peer-review. Please review the journal scope and author submission instructions prior to submitting a manuscript.

The deadline for submitting manuscripts is 31st December 2024. Please note normal Article Processing Charges apply.

Please submit your manuscript on our website, quoting the promo code OZOEM to indicate that your submission is for consideration in this Article Collection.

Please contact Marya Baig at [email protected] with any queries and discount codes regarding this Article Collection.

View all papers in this article collection

Dove Medical Press is pleased to invite you to the upcoming Article Collection “Biosimilars, Biobetters, and Bioparallels” led by Professor Ivo Abraham, Ms. Ansam Beddor, Dr. Nimer Alkhatib, and Dr. Karen MacDonald in Biologics: Targets and Therapy.

Looking back on almost three decades of biosimilars and despite their difficult start in Europe in 2015, biosimilars are solidly embedded in patient care and have become a mainstay in human therapeutics – at least in high income countries. Being equivalent in efficacy/effectiveness, safety and (mainly) priced lower than the originators they reference, biosimilars enable savings, expanded patient access, and greater patient equity. 

Furthermore, two recent developments have broadened the “later-in-class” biologics space beyond biosimilars. In October 2023, the United States Food and Drug Administration (FDA) approved Zymfentra, a subcutaneous (SC) formulation of Inflectra, an intravenous (IV) biosimilar referencing infliximab (Remicade). Rather peculiar but this SC formulation is approved in other jurisdictions as a biosimilar – along with its IV formulation – but in the US as a biological. Zymfentra is increasingly being referred to as a biobetter, in this case of a biosimilar (Inflectra) of originator infliximab (Remicade). Additional biobetters are on the horizon – as novel agents of biosimilar candidates that failed the upper bound of the equivalence margin. 

That same month, the FDA also approved toripalimab (Loqtorzi), the first Chinese PD-1 inhibitor based exclusively on Chinese clinical trials: not a biosimilar and neither a biobetter, but a bioparallel. It is a new biological molecule without the ambition of being an early-in-class innovator but instead a “later-in-class” entry, analogous (but not similar) in efficacy and safety, competing on price. There are more are on the horizon as well. 

While there can be clear benefits for adopting biosimilars, biobetters and bioparallels, many issues remain to be addressed: regulatory pathways; clinical evidence in support of regulatory approval; interchangeability; pricing and competition; commoditization of biological therapy; and the need for global access, especially in low, lower-middle and higher-middle income countries – among many others. 

To help address these issues, Biologics: Targets and Therapy invites authors to submit Original Research, Reviews, and Commentaries on relating to biosimilars, biobetters and bioparallels. Potential topics include but are not limited to:

• Clinical studies into the use of biosimilars, biobetters and bioparallels.
• Bioequivalence studies.
• Pharmacoeconomic analyses
• Research relating to the regulation, pricing, re-imbursement and market uptake of biosimilars, biobetters and bioparallels.

Keywords
Biosimilars, Biobetters, Bioparallels

All manuscripts submitted to this Article Collection will undergo desk assessment and a full peer-review. Please review the journal scope and author submission instructions prior to submitting a manuscript.

The deadline for submitting manuscripts is 31st January 2025. Please note normal Article Processing Charges apply.

Please submit your manuscript on our website, quoting the promo code ENTUK to indicate that your submission is for consideration in this Article Collection.

Please contact Marya Baig at [email protected] with any queries and discount codes regarding this Article Collection.

View all papers in this article collection